References
- Koenig H G, Blazes D G. Epidemiology of geriatric affective disorders. Clinics in Geriatric Medicine 1992; 8: 235–251
- Budman C L, Braun R D. Persistent dyskinesia in a patient receiving fluoxetine. American Journal of Psychiatry 1991; 148: 10
- Stein M H. Tardive dyskinesia in a patient taking haloperidol and fluoxetine. American Journal of Psychiatry 1991; 148: 638
- Burke R E. Tardive dyskinesia: current clinical issues. Neurology 1984; 34: 1348–1353
- Kane J M, Smith J M. Tardive dyskinesia: prevalence and risk factors, 1959–1979. Archives of General Psychiatry 1982; 39: 473–481
- Smith J M, Baldessarini R J. Changes in prevalence, severity and recovery in tardive dyskinesia with age. Archives of General Psychiatry 1980; 37: 1368–1373
- Jeste D V, Wyatt R J. Changing epidemiology of tardive dyskinesia: an overview. American Journal of Psychiatry 1981; 138: 297–309
- Munetz M R, Benjamin S. How to examine patients using the Abnormal Involuntary Movement Scale. Hospital and Community Psychiatry 1988; 39: 1172–1177
- Moore D C, Bowers M B. Identification of a subgroup of tardive dyskinesia patients by pharmacological probes. American Journal of Psychiatry 1980; 137: 1202–1205
- Barnes T RE. Tardive dyskinesia: risk factors, pathophysiology and treatment. Recent advances in clinical psychiatry, K Granville-Grossman. Churchill Livingstone, Edinburgh 1988; 185–207, No. 6
- Stahl S M, David K L, Berger P A. The neuropharpharmacology of tardive dyskinesia, spontaneous dyskinesia and other dystonias. Journal of Clinical Psychopharmacology 1982; 2: 321–343
- Baldessarini R J, Tarsy D. Mechanisms underlying tardive dyskinesia. The basal ganglia, M D Yahr. Raven Press, New York 1976; 433–452
- Bouchard R H, Pourcher E, Vincent P. Fluoxetine and extrapyramidal side effects. American Journal of Psychiatry 1989; 146: 1352–1353
- Brod T M. Fluoxetine and extrapyramidal side effects. American Journal of Psychiatry 1989; 146: 1353
- Lipinski J F, Mallya G, Zimmerman P, Pope H G. Fluoxetine-in-duced akathisia: clinical and theroretical implications. Journal of Clinical Psychiatry 1989; 50: 339–342
- Falcon B A, Liebowitz M R. Fluoxetine and extrapyramidal symptoms in CNS lupus. Journal of Clinical Psychopharmacology 1991; 11: 147–148
- Tate J L. Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine. American Journal of Psychiatry 1989; 146: 399–400
- Meltzer H Y, Young M, Metz J, Fang V S, Schyve P M, Arora R C. Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant. Journal of Neural Transmission 1979; 45: 165–175
- Baldessarini R J, Marsh E. Fluoxetine and side effects. Archives of General Psychiatry 1990; 47: 191–192
- Kozell L, Sandyk R, Wagner G C, Fisher H. The effects of L-tryptophan on haloperidol-induced movement disorder in the rat. Life Sciences 1987; 41: 1739–1744
- Fibiger H C, Lloyd K G. Neurobiological substracts of tardive dyskinesia: the GABA hypothesis. Trends in Neuroscience. 1984; 7: 462–464